Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30

Go back to Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30

Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital

August 9, 2024 6:26 AM EDT

RBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $8.00 (from $11.00) while maintaining a Sector Perform rating.

The analyst comments "Recent and newly disclosed manufacturing issues for INO-3107's CELLECTRA device push BLA submission for accelerated approval to... More